Polysomnography (PSG) is a comprehensive sleep study that serves as a critical diagnostic tool in the evaluation of atypical Parkinsonian syndromes, particularly for distinguishing between corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and related disorders. While these tauopathies share overlapping clinical features, their sleep profiles differ significantly from synucleinopathies, making PSG an invaluable component of the diagnostic workup[@arnulf2024].
This page provides a comprehensive guide to sleep testing for patients being evaluated for CBS or PSP, covering PSG protocols, interpretation of findings, and clinical decision-making based on results.
Sleep disturbances are ubiquitous in neurodegenerative diseases, but the pattern and severity of sleep abnormalities vary by pathology. In CBS and PSP, sleep dysfunction reflects the underlying tauopathy affecting brainstem and subcortical structures involved in sleep-wake regulation[@boeve2024].
Key sleep-related structures affected in tauopathies include:
Polysomnography (PSG) is a comprehensive sleep study that serves as a critical diagnostic tool in the evaluation of atypical Parkinsonian syndromes, particularly for distinguishing between corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and related disorders. While these tauopathies share overlapping clinical features, their sleep profiles differ significantly from synucleinopathies, making PSG an invaluable component of the diagnostic workup[@arnulf2024].
This page provides a comprehensive guide to sleep testing for patients being evaluated for CBS or PSP, covering PSG protocols, interpretation of findings, and clinical decision-making based on results.
Sleep disturbances are ubiquitous in neurodegenerative diseases, but the pattern and severity of sleep abnormalities vary by pathology. In CBS and PSP, sleep dysfunction reflects the underlying tauopathy affecting brainstem and subcortical structures involved in sleep-wake regulation[@boeve2024].
Key sleep-related structures affected in tauopathies include:
Both CBS and PSP are 4-repeat tauopathies with significant sleep pathology, but there are important distinctions:
| Sleep Parameter | CBS | PSP |
|-----------------|-----|-----|
| REM Sleep Behavior Disorder | 0-8% | 0-13% |
| Periodic Limb Movements | 50-70% | 60-80% |
| Sleep Efficiency | Reduced (60-75%) | Markedly reduced (50-65%) |
| Slow-Wave Sleep | Moderately reduced | Severely reduced |
| REM Sleep Percentage | Normal to slightly reduced | Significantly reduced |
A comprehensive PSG evaluation for CBS/PSP patients should include[@american2024]:
| Channel Type | Electrodes/Montage | Purpose |
|--------------|---------------------|---------|
| EEG | C3/A2, C4/A1, O1/A2, O2/A1, F3/A2, F4/A1 | Sleep staging, detect epileptiform activity |
| EOG | Left and right outer canthus | Eye movement detection, REM identification |
| Chin EMG | Submental (mentalis) + bilateral anterior tibialis | REM atonia assessment, PLMS detection |
| Limb EMG | Bilateral flexor digitorum superficialis | Phasic muscle activity, PLMS |
| Respiratory | Nasal pressure cannula, oral thermistor, chest/abdominal belts | Exclude sleep-disordered breathing |
| Pulse Oximetry | Continuous SpO2 monitoring | Detect nocturnal hypoxia |
| ECG | Single-lead | Cardiac rhythm monitoring |
| Extended Montage | 10-20 EEG system recommended | Enhanced sleep staging |
The gold standard for sleep evaluation in neurodegenerative disease. Benefits include[@littner2024]:
Attended or unattended full PSG performed at home. Acceptable alternative when in-lab testing is not feasible[@chesson2024]:
Minimum 4-channel devices for sleep-disordered breathing screening:
A typical night of sleep cycles through distinct stages:
Sleep efficiency (total sleep time / time in bed) is consistently reduced in both CBS and PSP[@martnezdubois2024]:
Slow-wave sleep is particularly vulnerable in tauopathies:
REM sleep percentage is reduced in PSP more than CBS[@iranzo2024]:
| Parameter | Normal | CBS | PSP |
|-----------|--------|-----|-----|
| REM % TST | 20-25% | 15-22% | 8-15% |
| REM Latency | 60-120 min | 60-150 min | 90-180 min |
| REM Density | Normal | Normal to increased | Reduced |
PLMS are extremely common in CBS and PSP[@sixeldring2024]:
| Feature | PLMS | RBD |
|---------|------|-----|
| Timing | N1/N2 sleep | REM sleep |
| Movement Type | Stereotypic kicks | Complex behaviors |
| Dream Recall | No | Yes (usually) |
| EMG Pattern | Phasic bursts | RSWA |
The polysomnographic hallmark of RBD is loss of normal REM sleep muscle atonia, measured as RSWA[@sixeldring2024a]:
| Parameter | Normal | RSWA Positive |
|-----------|--------|---------------|
| Tonic Chin EMG | <15% of REM epoch | >50% of REM epoch with amplitude >50% max |
| Phasic Chin EMG | <15% of REM epoch | >50% of REM epoch with bursts >4x background |
| Limb EMG (Upper) | Minimal activity | >50% of REM epoch with excessive activity |
Patients with RSWA may exhibit:
The presence or absence of RBD is one of the most powerful sleep-based biomarkers for differential diagnosis[@koga2024]:
If RBD is PRESENT in a patient with CBS/PSP phenotype:
Video recording during PSG is essential for:
The MSLT assesses daytime sleepiness and measures sleep latency and REM sleep occurrence[@carskadon2024]:
| Parameter | Normal | CBS | PSP |
|-----------|--------|-----|-----|
| Mean Sleep Latency | >8 min | 6-10 min | 4-8 min |
| SOREMPs | 0-2 | 0-1 | 0-2 |
Clinical significance:
Indications for PSG testing:
Patient with Parkinsonian Features
│
▼
PSG Evaluation
│
├─► RBD Present ──► Synucleinopathy Likely
│ │
│ ├─► Autonomic Failure ──► MSA
│ ├─► Cognitive Fluctuations ──► DLB
│ └─► Tremor-Dominant ──► PD
│
└─► RBD Absent ──► Tauopathy Likely
│
├─► Vertical Gaze Palsy ──► PSP
├─► Alien Limb/Apraxia ──► CBS
└─► Cortical Signs ──► CBD
| PSG Finding | Interpretation | Next Steps |
|-------------|---------------|------------|
| RSWA + RBD | Suggests synucleinopathy | Re-evaluate diagnosis |
| Normal REM atonia | Consistent with CBS/PSP | Continue standard workup |
| Severe sleep fragmentation | Advanced disease | Optimize treatment |
| Sleep apnea present | Comorbid SDB | Treat CPAP/BiPAP |
| PLMS prominent | May cause sleep disruption | Consider clonazepam or dopaminergic therapy |
Refer to a sleep specialist for PSG when[@international2024]:
Academic Sleep Centers with Movement Disorder Expertise:
| Component | Approximate Cost (USD) | Insurance Coverage |
|-----------|----------------------|---------------------|
| In-lab overnight PSG | $1,500 - $3,000 | Usually covered with clinical indication |
| Home sleep study | $300 - $800 | Usually covered |
| MSLT | $500 - $1,000 | Usually covered |
| Sleep medicine consultation | $150 - $400 | Covered as specialist visit |
Tips for insurance:
| PSG Finding | Treatment Implications |
|-------------|----------------------|
| RBD present | Avoid antidepressants that worsen RBD; treat RBD with clonazepam or melatonin |
| Sleep apnea | CPAP/BiPAP may improve motor symptoms and cognition |
| Severe fragmentation | Optimize sleep hygiene; consider sedating medications |
| PLMS | May respond to clonazepam or dopaminergic agents |
Polysomnography is an essential diagnostic tool in the evaluation of atypical Parkinsonian syndromes:
Early PSG evaluation in patients with parkinsonian features can significantly improve diagnostic accuracy and guide appropriate management.
The following diagram shows the key molecular relationships involving Polysomnography and Sleep Study Testing for Atypical Parkinsonism discovered through SciDEX knowledge graph analysis: